Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and Durvalumab in High-Risk Hepatocellular Carcinoma
NCT05194293Phase 2Active, not recruiting
- Sponsor
- Academic and Community Cancer Research United
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, regorafenib in hepatocellular carcinoma (HCC), sponsored by Academic and Community Cancer Research United. Started Jul 2023; status: active, not recruiting.
02
Drugs
durvalumabregorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05194293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05194293.